about
Neuroblastoma patients with high-affinity FCGR2A, -3A and stimulatory KIR 2DS2 treated by long-term infusion of anti-GD2 antibody ch14.18/CHO show higher ADCC levels and improved event-free survival.Inflammatory response and treatment tolerance of long-term infusion of the anti-GD2 antibody ch14.18/CHO in combination with interleukin-2 in patients with high-risk neuroblastoma.PD-1 blockade augments anti-neuroblastoma immune response induced by anti-GD2 antibody ch14.18/CHO.Impact of HACA on Immunomodulation and Treatment Toxicity Following ch14.18/CHO Long-Term Infusion with Interleukin-2: Results from a SIOPEN Phase 2 TrialCo-expression of IL-15 enhances anti-neuroblastoma effectivity of a tyrosine hydroxylase-directed DNA vaccination in miceLow CD4⁺/CD25⁺/CD127⁻ regulatory T cell- and high INF-γ levels are associated with improved survival of neuroblastoma patients treated with long-term infusion of ch14.18/CHO combined with interleukin-2GD2 targeting by dinutuximab beta is a promising immunotherapeutic approach against malignant glioma
P50
Q41689901-6FFCDDC3-923B-43B8-8A69-BA17E9D13CD2Q48208790-184D47B7-0E05-456E-BE72-A4CD81BF457FQ50445794-D6FADDD6-8E6E-48B0-AE1B-36C61B727E6CQ58605647-933BE4B9-0C8D-438B-8DE4-A8165255770EQ59796509-CCAA2D4C-C859-4E5B-BF0B-76DF641CE9A1Q91333547-8CBA9247-382C-4FAD-9F2C-0CB14C2BE9DFQ91558117-C36153AA-E0A2-41E9-8269-B0DA5D1573DE
P50
description
onderzoeker
@nl
researcher ORCID ID = 0000-0002-6185-462X
@en
name
Sascha Troschke-Meurer
@ast
Sascha Troschke-Meurer
@en
Sascha Troschke-Meurer
@es
Sascha Troschke-Meurer
@nl
type
label
Sascha Troschke-Meurer
@ast
Sascha Troschke-Meurer
@en
Sascha Troschke-Meurer
@es
Sascha Troschke-Meurer
@nl
prefLabel
Sascha Troschke-Meurer
@ast
Sascha Troschke-Meurer
@en
Sascha Troschke-Meurer
@es
Sascha Troschke-Meurer
@nl
P106
P31
P496
0000-0002-6185-462X